Scholarlink

<p>In multiple sclerosis (MS), the retina can be affected by acute inflammation during optic neuritis and by chronic neurodegeneration involving retinal cells. Teriflunomide is an approved immunomodulatory therapy that reduces relapse rates, but its potential to mitigate chronic retinal damage in MS remains unclear. We conducted a prospective, open-label study including 15 patients (87% females, mean ± SD age of 46.5 ± 6.2&#xa0;years-old) with RRMS initiating teriflunomide as standard of care. Assessments were performed at baseline and after 12&#xa0;months, including best-corrected visual acuity, neurological disability (Expanded Disability Status Scale, EDSS), retinal layer thickness by optical coherence tomography (OCT), and multifocal electroretinography (mfERG) to evaluate retinal cell function. During follow-up, patients remained clinically stable with no relapses, optic neuritis episodes, or significant changes in EDSS or visual acuity. After 12&#xa0;months of treatment, mfERG analysis revealed a statistically significant overall wave amplitude mean increase in P1 (+ 21.6%, <i>p</i> = 0.039) and a non-significant mean increase in N1 (+ 17.5%, <i>p</i> = 0.143) and N2 amplitude (+ 11%, <i>p</i> = 0.851). One year of teriflunomide therapy was associated with functional improvement in retinal electrophysiological responses in clinically stable MS patients.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Multifocal ERG reveals functional retinal changes in multiple sclerosis patients treated with teriflunomide: a 12-month prospective study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月24日

查看全文
  • Marc Figueras-Roca,
  • Juan Laraña,
  • Anna Camós-Carreras,
  • Salut Alba-Arbalat,
  • Erika Sánchez-Vela,
  • Sara Llufriu,
  • Pablo Villoslada,
  • Bernardo Sánchez-Dalmau

摘要

In multiple sclerosis (MS), the retina can be affected by acute inflammation during optic neuritis and by chronic neurodegeneration involving retinal cells. Teriflunomide is an approved immunomodulatory therapy that reduces relapse rates, but its potential to mitigate chronic retinal damage in MS remains unclear. We conducted a prospective, open-label study including 15 patients (87% females, mean ± SD age of 46.5 ± 6.2 years-old) with RRMS initiating teriflunomide as standard of care. Assessments were performed at baseline and after 12 months, including best-corrected visual acuity, neurological disability (Expanded Disability Status Scale, EDSS), retinal layer thickness by optical coherence tomography (OCT), and multifocal electroretinography (mfERG) to evaluate retinal cell function. During follow-up, patients remained clinically stable with no relapses, optic neuritis episodes, or significant changes in EDSS or visual acuity. After 12 months of treatment, mfERG analysis revealed a statistically significant overall wave amplitude mean increase in P1 (+ 21.6%, p = 0.039) and a non-significant mean increase in N1 (+ 17.5%, p = 0.143) and N2 amplitude (+ 11%, p = 0.851). One year of teriflunomide therapy was associated with functional improvement in retinal electrophysiological responses in clinically stable MS patients.